-
Vitae Pharmaceuticals Inc (NASDAQ: VTAE) shares
climbed 158.5 percent to $20.94. Allergan plc (NYSE: AGN) and Vitae Pharmaceuticals reached an agreement by which the former would buy
the latter for $21.00 a share in cash.
-
Biostar Pharmaceuticals Inc (NASDAQ: BSPM) shares
surged 66.8 percent to $3.42. Biostar shares have dropped 54.24 percent over the past 52 weeks, while the S&P 500 index has
gained 8.91 percent in the same period.
-
Sarepta Therapeutics Inc (NASDAQ: SRPT) gained
25.1 percent to $32.01. Dr. Ron Farkas has left the U.S. Food & Drug Administration, people familiar with the matter told
Benzinga. Farkas was the most vocal critic of Sarepta's eteplirsen, although there were other FDA members who agreed there was
little efficacy for the drug.
-
StemCells Inc (NASDAQ: STEM) shares rose 23.9
percent to $1.62. StemCells shares have tumbled 78.59 percent over the past 52 weeks, while the S&P 500 index has increased
8.91 percent in the same period.
-
Acasti Pharma Inc (NASDAQ: ACST) shares gained
23.6 percent to $1.56 after the company reported positive CaPre Omega-3 bridging study data.
-
Morgans Hotel Group Co. (NASDAQ: MHGC) rose 21.5
percent to $2.15 as the company disclosed that it has received a revised takeover proposal of $2.75 per share.
-
Red Lion Hotels Corporation (NYSE: RLH) shares
gained 12.2 percent to $7.90. Red Lion Hotels reported the purchase of Vantage Hospitality Group.
-
Exelixis, Inc. (NASDAQ: EXEL) climbed 6.3 percent
to $13.08 after the company disclosed that the EC has approved CABOMETYX tablets for the treatment of advanced renal cell
carcinoma following VEGF-targeted therapy.
-
Arctic Cat Inc (NASDAQ: ACAT) rose 5.4 percent to
$14.46. Wunderlich upgraded Arctic Cat from Sell to Hold.
-
Asterias Biotherapeutics Inc (NYSE: AST) shares
gained 5.4 percent to $3.88 after the company reported positive efficacy data in patients with complete cervical spinal cord
injuries treated with AST-OPC1.
-
At Home Group Inc. (NASDAQ: HOME) shares rose 4.7
percent to $13.03. At Home Group reported Q2 earnings of $0.13 per share on sales of $188.4 million. The company expects FY17
earnings of $0.53 to $0.56 per share on revenue of $738 million to $750 million. Guggenheim Securities upgraded At Home Group
from Neutral to Buy.
-
Herbalife Ltd. (NYSE: HLF) shares rose 4.5 percent
to $62.53 following Carl Icahn comments at the Delivering Alpha conference Tuesday afternoon.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.